At Alaya.bio, we're developing a revolutionary targeting polymeric nanoparticle that enhances the transduction efficiency of quiescent cells such as T-cells, NK-cells, and stem cells. Our platform eliminates the need for activation factors or cytokines, resulting in reduced exhaustion of transduced cells while preserving their naive and memory phenotypes, leading to better clinical outcomes.
Company Details
- Employees
- 22
- Founded
- -
- Address
- 139 Main Street, Cambridge,united States
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- http://www.alaya.bio
- HQ
- Cambridge
Alaya.bio Questions
Alaya.Bio's website is http://www.alaya.bio
Alaya.Bio's LinkedIn profile is https://www.linkedin.com/company/alayabio
Alaya.Bio has
22 employees.
View email and phone details for 22
employees at Alaya.Bio.
Alaya.Bio's industry is
Biotechnology Research
Alaya.Bio's top competitors are
Viralgen,
Century Therapeutics, Inc,
Myeloid Therapeutics,
Nanocell Therapeutics,
Carisma Therapeutics,
Genprex, Inc.,
Ixaka,
Interius Biotherapeutics,
Cellfe,
Kelonia Therapeutics.
Alaya.Bio's categories are Biotechnology Research
Alaya.Bio's founding year is 2022
